PALOMA 3 Trial Overview: Mechanisms & Outcomes 📊

Created using ChatSlide

This presentation investigates the comparative efficacy and utilisation of subcutaneous (SC) versus intravenous (IV) treatments for patients with EGFR-mutated non-small cell lung cancer (NSCLC). Encompassing 418 patients, the study assesses key metrics such as pharmacokinetics, overall response rates (ORR), and progression-free survival (PFS), revealing a noteworthy overall survival (OS) advantage and enhanced safety profile in SC treatment. Additional analysis highlights the reduced...